RABL2A

Summary

RABL2A (RAB, member of RAS oncogene family like 2A, HGNC:9799) is a protein-coding gene on chromosome 2q14.1, encoding Rab-like protein 2A (Q9UBK7). Small GTPase that plays an essential role in male fertility, sperm intra-flagellar transport, and tail assembly. It is a selective cancer dependency (DepMap: 17.6% of cell lines).

This gene is a member of the RAB gene family which belongs to the RAS GTPase superfamily. The proteins in the family of RAS-related signaling molecules are small GTP-binding proteins that play important roles in the regulation of exocytotic and endocytotic pathways. This gene maps to the site of an ancestral telomere fusion event and may be a subtelomeric gene. Alternative splicing results in multiple transcript variants encoding different isoforms.

Source: NCBI Gene 11159 — RefSeq curated summary.

At a glance

• Gene–disease (curated): infertility disorder (Limited, GenCC)
• Clinical variants (ClinVar): 43 total
• Cancer dependency (DepMap): dependent in 17.6% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency dosage sensitivity unlikely, triplosensitivity no evidence
• MANE Select transcript: NM_001306158

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9799
Approved symbol	RABL2A
Name	RAB, member of RAS oncogene family like 2A
Location	2q14.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000144134
Ensembl biotype	protein_coding
OMIM	605412
Entrez	11159

Gene structure

Transcript identifiers

Ensembl transcripts: 51 — 40 protein_coding, 6 retained_intron, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000376439, ENST00000393165, ENST00000393166, ENST00000393167, ENST00000409121, ENST00000409842, ENST00000409875, ENST00000413545, ENST00000450954, ENST00000452831, ENST00000465711, ENST00000467600, ENST00000476236, ENST00000477218, ENST00000478880, ENST00000486403, ENST00000493876, ENST00000494909, ENST00000683472, ENST00000896779, ENST00000896780, ENST00000896781, ENST00000896782, ENST00000896783, ENST00000896784, ENST00000896785, ENST00000896786, ENST00000896787, ENST00000896788, ENST00000896789, ENST00000896790, ENST00000896791, ENST00000896792, ENST00000896793, ENST00000896794, ENST00000924793, ENST00000924794, ENST00000924795, ENST00000924796, ENST00000924797, ENST00000924798, ENST00000924799, ENST00000924800, ENST00000965202, ENST00000965203, ENST00000965204, ENST00000965205, ENST00000965206, ENST00000965207, ENST00000965208, ENST00000965209

RefSeq mRNA: 26 — MANE Select: NM_001306158 NM_001306158, NM_001306159, NM_001306160, NM_001306161, NM_001354405, NM_001354406, NM_001354407, NM_001354408, NM_001354409, NM_001354410, NM_001354412, NM_001354413, NM_001354414, NM_001354416, NM_001354417, NM_001354418, NM_001354419, NM_001354421, NM_001354423, NM_001354424, NM_001354425, NM_001354426, NM_001354427, NM_001354428, NM_007082, NM_013412

CCDS: CCDS2118, CCDS77454, CCDS77455, CCDS77456

Canonical transcript exons

ENST00000683472 — 9 exons

Exon	Start	End
ENSE00002497663	113628554	113628713
ENSE00003464258	113632915	113632944
ENSE00003482362	113634153	113634232
ENSE00003489181	113635051	113635130
ENSE00003518017	113641781	113641864
ENSE00003551833	113641353	113641450
ENSE00003594561	113640894	113641005
ENSE00003648382	113642031	113643392
ENSE00003921955	113627266	113627400

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 99.46.

FANTOM5 (CAGE): breadth broad, TPM avg 1.5675 / max 22.9176, expressed in 810 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
22160	1.5675	810

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	99.46	gold quality
fallopian tube	UBERON:0003889	94.83	gold quality
right lobe of thyroid gland	UBERON:0001119	94.73	gold quality
left lobe of thyroid gland	UBERON:0001120	94.18	gold quality
pituitary gland	UBERON:0000007	94.16	gold quality
thyroid gland	UBERON:0002046	94.16	gold quality
right hemisphere of cerebellum	UBERON:0014890	93.97	gold quality
cerebellar hemisphere	UBERON:0002245	93.71	gold quality
cerebellar cortex	UBERON:0002129	93.68	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.65	gold quality
cerebellum	UBERON:0002037	93.59	gold quality
adenohypophysis	UBERON:0002196	93.51	gold quality
metanephros cortex	UBERON:0010533	93.27	gold quality
nucleus accumbens	UBERON:0001882	93.20	gold quality
endocervix	UBERON:0000458	93.04	gold quality
left ovary	UBERON:0002119	92.89	gold quality
right ovary	UBERON:0002118	92.87	gold quality
caudate nucleus	UBERON:0001873	92.83	gold quality
body of uterus	UBERON:0009853	92.83	gold quality
superior frontal gyrus	UBERON:0002661	92.78	gold quality
left uterine tube	UBERON:0001303	92.68	gold quality
ovary	UBERON:0000992	92.36	gold quality
primary visual cortex	UBERON:0002436	92.26	gold quality
right frontal lobe	UBERON:0002810	92.14	gold quality
left testis	UBERON:0004533	92.00	gold quality
Ammon’s horn	UBERON:0001954	91.99	gold quality
right testis	UBERON:0004534	91.93	gold quality
brain	UBERON:0000955	91.66	gold quality
prostate gland	UBERON:0002367	91.61	gold quality
hypothalamus	UBERON:0001898	91.57	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.01

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

61 targeting RABL2A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-652-5P	99.91	67.49	505
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3975	99.62	65.97	697
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-4728-3P	99.47	68.94	981
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-2392	99.43	67.50	708
HSA-MIR-889-5P	99.41	68.75	1025
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620

Functional genomics

ClinGen dosage: haploinsufficiency 40 (dosage sensitivity unlikely), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 17.6% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 6)

• In human samples no deviations of the euploid genomic state could be detected indicating that 22q13 microdeletions involving RABL2B are rare. (PMID:20138207)
• Suggest the 114391996 delC allele in the RABL2A gene may act as a risk factor for oligoasthenospermic infertility in Australian men. (PMID:24825419)
• RABL2 controls localization of GPR161 independently of TULP3, which promotes entry of ciliary GPCRs. (PMID:30578315)
• Variants in RABL2A causing male infertility and ciliopathy. (PMID:33075816)
• RABL2A-CCDC34 Axis Promotes Sorafenib Resistance in Hepatocellular Carcinoma. (PMID:34767735)
• Architecture of RabL2-associated complexes at the ciliary base: A structural modeling perspective: Deciphering the structural organization of ciliary RabL2 complexes. (PMID:38991980)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rabl2	ENSDARG00000063321
mus_musculus	Rabl2	ENSMUSG00000022621
rattus_norvegicus	Rabl2	ENSRNOG00000013947

Paralogs (68): RAB27B (ENSG00000041353), RAB27A (ENSG00000069974), RAB7A (ENSG00000075785), RABL2B (ENSG00000079974), RAB21 (ENSG00000080371), RAB10 (ENSG00000084733), RAB18 (ENSG00000099246), RAB36 (ENSG00000100228), IFT27 (ENSG00000100360), RAB40AL (ENSG00000102128), RAB11A (ENSG00000103769), RAB2A (ENSG00000104388), RAB3D (ENSG00000105514), RAB3A (ENSG00000105649), RAB5C (ENSG00000108774), RAB34 (ENSG00000109113), RAB5B (ENSG00000111540), RAB35 (ENSG00000111737), RAB23 (ENSG00000112210), DNAJC27 (ENSG00000115137), RAB29 (ENSG00000117280), RAB32 (ENSG00000118508), RAB14 (ENSG00000119396), RAB9B (ENSG00000123570), RAB9A (ENSG00000123595), RAB38 (ENSG00000123892), RAB22A (ENSG00000124209), RAB17 (ENSG00000124839), RAB2B (ENSG00000129472), RAB25 (ENSG00000132698), RAB33A (ENSG00000134594), RAB30 (ENSG00000137502), RAB1A (ENSG00000138069), RAB20 (ENSG00000139832), RAB15 (ENSG00000139998), RAB40B (ENSG00000141542), RAB13 (ENSG00000143545), RAB5A (ENSG00000144566), RAB19 (ENSG00000146955), RAB41 (ENSG00000147127)

Protein

Protein identifiers

Rab-like protein 2A — Q9UBK7 (reviewed: Q9UBK7)

All UniProt accessions (6): Q9UBK7, B7ZBD4, B7ZBD5, E7EWW3, F2Z2E5, Q6IC14

UniProt curated annotations — full annotation on UniProt →

Function. Small GTPase that plays an essential role in male fertility, sperm intra-flagellar transport, and tail assembly. Binds, in a GTP-regulated manner, to a specific set of effector proteins including key proteins involved in cilia development and function and delivers them into the growing sperm tail.

Subunit / interactions. Interacts with IFT27, IFT81, IFT172, ATP6V1E1, HK1, LDHC, MAPRE1 and HSPA2.

Tissue specificity. Expressed in the testis.

Domain organisation. Switch I, switch II and the interswitch regions are characteristic of Rab GTPases and mediate the interactions with Rab downstream effectors. The switch regions undergo conformational changes upon nucleotide binding which drive interaction with specific sets of effector proteins, with most effectors only binding to GTP-bound Rab.

Similarity. Belongs to the small GTPase superfamily. Rab family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UBK7-1	1	yes
Q9UBK7-2	2
Q9UBK7-3	3

RefSeq proteins (26): NP_001293087, NP_001293088, NP_001293089, NP_001293090, NP_001341334, NP_001341335, NP_001341336, NP_001341337, NP_001341338, NP_001341339, NP_001341341, NP_001341342, NP_001341343, NP_001341345, NP_001341346, NP_001341347, NP_001341348, NP_001341350, NP_001341352, NP_001341353, NP_001341354, NP_001341355, NP_001341356, NP_001341357, NP_009013, NP_038198 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR041835	RabL2	Family

Pfam: PF00071

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (20 total): binding site 14, region of interest 3, splice variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UBK7-F1	79.80	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (14): 53; 53; 76; 79; 133; 134; 136; 160; 30; 31; 33; 34 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 59 (showing top): GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_CILIUM_ORGANIZATION, GOBP_ORGANELLE_ASSEMBLY, GOBP_CELL_PROJECTION_ORGANIZATION, chr2q14, GOCC_CILIUM, GOMF_GTPASE_ACTIVITY, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, GOBP_INTRACELLULAR_TRANSPORT, FOXN3_TARGET_GENES, IRF5_TARGET_GENES, NCOA2_TARGET_GENES, ZSCAN2_TARGET_GENES, MIR4261, MIR147B_5P

GO Biological Process (3): intracellular protein transport (GO:0006886), microtubule-based movement (GO:0007018), cilium assembly (GO:0060271)

GO Molecular Function (5): GTPase activity (GO:0003924), G protein activity (GO:0003925), GTP binding (GO:0005525), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (2): cilium (GO:0005929), endomembrane system (GO:0012505)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular protein localization	1
protein transport	1
intracellular transport	1
microtubule-based process	1
axoneme assembly	1
intraciliary transport involved in cilium assembly	1
cilium organization	1
protein localization to cilium	1
organelle assembly	1
trans-Golgi to periciliary membrane compartment transport	1
plasma membrane bounded cell projection assembly	1
ciliary transition zone assembly	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
molecular function regulator activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
vacuole	1
plasma membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2193 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RABL2A	SHANK3	Q9BYB0	923
RABL2A	APPL2	Q8NEU8	895
RABL2A	CEP19	Q96LK0	809
RABL2A	ALG12	Q9BV10	752
RABL2A	IFT22	Q9H7X7	553
RABL2A	PIM3	Q86V86	552
RABL2A	RABGEF1	Q9UJ41	493
RABL2A	SHANK2	Q9UPX8	471
RABL2A	SULT4A1	Q9BR01	447
RABL2A	IFT27	Q9BW83	437
RABL2A	CCDC60	Q8IWA6	434
RABL2A	TBC1D22A	Q8WUA7	434
RABL2A	ARL13B	Q3SXY8	430
RABL2A	CPLX1	O14810	424
RABL2A	TEPSIN	Q96N21	419

IntAct

14 interactions, top by confidence:

A	B	Type	Score
RPP25	POP7	psi-mi:“MI:0914”(association)	0.810
CEP19	CEP43	psi-mi:“MI:0914”(association)	0.770
CEP19	RABL2A	psi-mi:“MI:0915”(physical association)	0.550
BMP2K	RABL2A	psi-mi:“MI:0915”(physical association)	0.490
M		psi-mi:“MI:0914”(association)	0.350
PRKY	METTL15	psi-mi:“MI:0914”(association)	0.350
HNRNPCL2	SMCHD1	psi-mi:“MI:0914”(association)	0.350
CCT8L2	DVL2	psi-mi:“MI:0914”(association)	0.350
RPP25	RPP40	psi-mi:“MI:0914”(association)	0.350
RABL2A	CEP43	psi-mi:“MI:0914”(association)	0.350
CCDC34	ACTBL2	psi-mi:“MI:0914”(association)	0.350
EEF1AKMT3	SMCHD1	psi-mi:“MI:0914”(association)	0.350

BioGRID (38): CEP19 (Two-hybrid), RABL2A (Affinity Capture-MS), RABL2A (Affinity Capture-MS), AKAP11 (Affinity Capture-MS), VPS13A (Affinity Capture-MS), ALMS1 (Affinity Capture-MS), MTO1 (Affinity Capture-MS), BRCA2 (Affinity Capture-MS), POLA1 (Affinity Capture-MS), TP73 (Affinity Capture-MS), TTF2 (Affinity Capture-MS), RABL2A (Affinity Capture-MS), RABL2A (Affinity Capture-MS), FIGNL1 (Affinity Capture-MS), FHIT (Affinity Capture-MS)

ESM2 similar proteins: A0A8I5ZNK2, A1L1L6, A2YNT8, A9TF79, D4AE59, E9Q9D5, O54833, O95057, P19784, P20427, P24786, P43291, P43292, P49137, P49138, P87027, Q0D4J7, Q0GGW5, Q16288, Q16644, Q2HJF8, Q32LJ6, Q4R4K5, Q5E9J4, Q5FVJ7, Q5IFJ9, Q5IS37, Q5N942, Q5R573, Q5ZKR4, Q66H84, Q6NVC5, Q6ZI44, Q75H77, Q75LR7, Q75V57, Q7XQP4, Q8BG51, Q8IXI2, Q91604

Diamond homologs: E9Q9D5, G4MYS1, I1RMF2, O01803, O04486, O35509, O42819, O49513, O76173, O94655, P07560, P10536, P11620, P22125, P22129, P24408, P28185, P28187, P28188, P31584, P32939, P33519, P33723, P34139, P34140, P35293, P36412, P38545, P38555, P40392, P40393, P41924, P46638, P51151, P62490, P62491, P62492, P62493, P62494, P62820

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2520 predictions. Top by Δscore:

Variant	Effect	Δscore
2:113628714:G:GG	donor_gain	1.0000
2:113641776:CCCA:C	acceptor_loss	1.0000
2:113641777:CCAG:C	acceptor_loss	1.0000
2:113641778:CA:C	acceptor_loss	1.0000
2:113641779:A:AG	acceptor_gain	1.0000
2:113641779:AGCTC:A	acceptor_loss	1.0000
2:113641780:G:GA	acceptor_gain	1.0000
2:113641780:GCT:G	acceptor_gain	1.0000
2:113641860:TCGAG:T	donor_loss	1.0000
2:113641862:GAGG:G	donor_loss	1.0000
2:113641863:AGG:A	donor_loss	1.0000
2:113641864:GGTA:G	donor_loss	1.0000
2:113641865:GTAG:G	donor_loss	1.0000
2:113642029:A:AG	acceptor_gain	1.0000
2:113642030:G:GG	acceptor_gain	1.0000
2:113642106:G:GT	donor_gain	1.0000
2:113642126:C:G	donor_gain	1.0000
2:113627267:G:GT	donor_gain	0.9900
2:113627401:G:GG	donor_gain	0.9900
2:113628549:GACA:G	acceptor_gain	0.9900
2:113628699:A:AG	donor_gain	0.9900
2:113628700:G:GG	donor_gain	0.9900
2:113632909:TTACA:T	acceptor_loss	0.9900
2:113632910:TACA:T	acceptor_loss	0.9900
2:113632911:ACAG:A	acceptor_loss	0.9900
2:113632912:CAGA:C	acceptor_loss	0.9900
2:113632913:A:AG	acceptor_gain	0.9900
2:113632913:A:T	acceptor_loss	0.9900
2:113632914:G:GA	acceptor_loss	0.9900
2:113632914:G:GG	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000348867 (2:113643839 C>A), RS1000687582 (2:113642484 T>A,C), RS1001245638 (2:113631331 A>G), RS1001300608 (2:113626696 G>A,T), RS1001631114 (2:113631066 T>G), RS1001658289 (2:113642680 C>G,T), RS1001966488 (2:113629796 C>T), RS1001993805 (2:113641269 T>A,C), RS1002360238 (2:113641066 C>T), RS1002565642 (2:113635669 C>T), RS1002677328 (2:113639644 T>C), RS1002917626 (2:113629950 T>G), RS1003247820 (2:113629006 G>A), RS1003555289 (2:113640396 A>G), RS1003637709 (2:113628853 G>A,C)

Disease associations

OMIM: gene MIM:605412 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
infertility disorder	Limited	Autosomal dominant

Mondo (1): infertility disorder (MONDO:0005047)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007246	Infertility	C12.100.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Smoke	decreases expression, increases abundance, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
GSK-J4	decreases expression	1
bisphenol F	affects cotreatment, increases expression	1
bisphenol A	affects cotreatment, increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
CGP 52608	affects binding, increases reaction	1
(+)-JQ1 compound	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Leflunomide	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	decreases expression, increases abundance, affects cotreatment	1
Cadmium	decreases expression, increases abundance	1
Cisplatin	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	affects expression	1
Hydrogen Peroxide	affects expression	1
Indomethacin	affects cotreatment, increases expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Methylcholanthrene	affects binding, increases reaction	1
Plant Extracts	affects cotreatment, decreases expression	1
Urethane	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Aflatoxin B1	increases methylation	1
Gold Compounds	increases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

103 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01388907	PHASE4	COMPLETED	Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery
NCT01430650	PHASE4	COMPLETED	Endometrial Priming for Embryo Transfer
NCT02607319	PHASE4	COMPLETED	Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure
NCT03169166	PHASE4	COMPLETED	The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
NCT03177122	PHASE4	UNKNOWN	Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
NCT03477929	PHASE4	UNKNOWN	Cetrorelix and Ganirelix Flexible Protocol for (IVF)
NCT03619707	PHASE4	COMPLETED	Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles
NCT03846544	PHASE4	COMPLETED	Double Pick up in Poor Prognosis Women
NCT05725512	PHASE4	RECRUITING	Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages
NCT06195163	PHASE4	NOT_YET_RECRUITING	TRAP Study: Testosterone for Androgen Receptor Polymorphism
NCT06763926	PHASE4	NOT_YET_RECRUITING	Intranasal Nafarelin For Triggering Oocyte Maturation
NCT00749853	PHASE3	SUSPENDED	Efficacy of Ovarian Stimulation Based on FSHR Genotype Status
NCT03238092	PHASE3	UNKNOWN	Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort
NCT03803228	PHASE3	COMPLETED	Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders
NCT04701034	PHASE2	COMPLETED	Intravenous Immunoglobulin and Prednisolone for RPL After ART.
NCT04850261	PHASE2	WITHDRAWN	Injection Free IVF
NCT06997900	PHASE2	RECRUITING	Menopur And Rekovelle Combination Study Version 2.0
NCT01330771	Not specified	COMPLETED	Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP
NCT01330784	Not specified	COMPLETED	Assessment of the Therapeutic Utility of hMG-HP
NCT01331720	Not specified	COMPLETED	Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation
NCT01331733	Not specified	COMPLETED	Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
NCT01406964	Not specified	COMPLETED	Chlamidia Antibodies Test for Tubal Factor Screening
NCT01533350	Not specified	COMPLETED	Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase
NCT01955356	Not specified	COMPLETED	Embryo Implantation After Induced Endometrial Injury
NCT02081924	Not specified	RECRUITING	Reproductive Hormones During Sustained Administration of Kisspeptin
NCT02648555	Not specified	UNKNOWN	A Lifestyle Intervention to Improve in Vitro Fertilization Results
NCT03007043	Not specified	COMPLETED	Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes and Suboptimal Response
NCT03023774	Not specified	COMPLETED	Use of Gcsf in Patients With Recurrent Ivf/Icsi Failure
NCT03065114	Not specified	COMPLETED	Retrospective Study on Clinical Results of Preimplantation Genetic Screening at Different Embryo Stage
NCT03085212	Not specified	ACTIVE_NOT_RECRUITING	Strategies for Pregnancy Achievement
NCT03085433	Not specified	COMPLETED	Sperm Selection by Microfluidic Separation Improves Embryo Quality
NCT03118219	Not specified	COMPLETED	Positive Adjustment Coping Intervention
NCT03156374	Not specified	COMPLETED	Timing Frozen Embryo Transfer by Following Two Different Methods
NCT03161873	Not specified	COMPLETED	Cycle and Pregnancy Monitoring With Wearable Sensor Technology (AVA)
NCT03173404	Not specified	COMPLETED	Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection
NCT03180827	Not specified	ACTIVE_NOT_RECRUITING	Female Fertility Preservation Using Ovarian Tissue Cryopreservation Before Highly Gonadotoxic Cancer Treatment
NCT03180918	Not specified	RECRUITING	Male Fertility Preservation Using Cryopreservation of Testicular Tissue Before Highly Gonadotoxic Cancer Treatment
NCT03250195	Not specified	TERMINATED	Non-invasive Detection of Male Infertility With FDG-PET/MRI (Spectroscopy and DWI)
NCT03269916	Not specified	UNKNOWN	Fertility and Ovarian Reserve Function in the Patient With Inflammatory Bowel Disease
NCT03290911	Not specified	COMPLETED	Retrospective Trial on Low Prognosis Infertile Patients